Novel Primate T-cell Lymphotropic Viruses (HTLV, STLV) for Development of Diagnostics, Therapeutics, Research Tools, and Vaccines
Rapid Detection of Antiretroviral(s) Drug-Resistant HIV-1 within Clinical Samples
Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis
Molecular Detection and Viral-Load Quantification for HIV-1 Groups M, N and O, and Simian Immunodeficiency Virus-cpz (SIVcpz)
Simple, Rapid, and Sensitive Real-Time PCR Assays for Detecting Drug Resistance of HIV
Multiplexing Homocysteine in Primary Newborn Screening Assays Using Maleimides as Select Derivatization Agents
P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain
This technology includes the development of selective P2Y14R antagonists for the treatment of asthma, sterile inflammation of the kidney, diabetes, and neurodegeneration. The P2Y14 receptor (P2Y14R) is a target for the treatment of inflammatory diseases, including pulmonary and renal conditions. Selective P2Y14R antagonists have demonstrated efficacy in animal models of asthma, pain, diabetes, and acute kidney injury. However, the prototypical antagonist is not optimal for in vivo administration, as it displays a low oral bioavailability.
Renal Selective Unsaturated Englerin Analogues
Englerin A, a natural product, has shown growth-inhibiting activity against renal cancer cell lines. The compound is an agonist of protein kinase C (PCK) theta, which results in cell cytotoxicity, insulin inhibition, and selective activation of viral replication in T cells. Englerin A derivatives are promising treatment strategies for any diseases associated with PKC theta and/or ion channel proteins.